Impact of Delays between Clinical and Laboratory Standards Institute and Food and Drug Administration Revisions of Interpretive Criteria for Carbapenem-Resistant Enterobacteriaceae
Impact of Delays between Clinical and Laboratory Standards Institute and Food and Drug Administration Revisions of Interpretive Criteria for Carbapenem-Resistant Enterobacteriaceae
复制标题
DOI：
10.1128/jcm.00635-16
复制
发表时间：
2016-11-01
影响因子：
9.4
通讯作者：
Lee, Bruce Y.
中科院分区：
文献类型：
--
作者：
Bartsch, Sarah M.;Huang, Susan S.;Lee, Bruce Y.
在CLSI和FDA修订抗菌解释标准之间经常发生延迟。使用我们的区域医疗保健生态系统分析师（RHEA）模拟模型，我们发现改变碳青霉烯类耐药肠杆菌科（CRE）断点的32个月延迟可能导致加利福尼亚州橙子县增加1，821名携带者，这一结果本可以通过识别CRE并启动接触预防措施来避免。当遏制传播至关重要时，政策制定者应致力于最大限度地减少对新出现的病原体采用抗菌剂新断点的延迟;延迟< 1.5年是理想的。
Delays often occur between CLSI and FDA revisions of antimicrobial interpretive criteria. Using our Regional Healthcare Ecosystem Analyst (RHEA) simulation model, we found that the 32-month delay in changing carbapenem-resistant Enterobacteriaceae (CRE) breakpoints might have resulted in 1,821 additional carriers in Orange County, CA, an outcome that could have been avoided by identifying CRE and initiating contact precautions. Policy makers should aim to minimize the delay in the adoption of new breakpoints for antimicrobials against emerging pathogens when containment of spread is paramount; delays of < 1.5 years are ideal.